Group 1 - The company Baicheng Pharmaceutical (SZ 301096) announced that several directors and senior management personnel plan to reduce their shareholdings through centralized bidding within three months after 15 trading days from the announcement date [1][2] - Director Jia Fei plans to reduce his holdings by up to 12,200 shares, accounting for 0.0112% of the total share capital [1] - Director Song Bofan plans to reduce her holdings by up to 2,300 shares, accounting for 0.0021% of the total share capital [1] - Director Yan Hongbing plans to reduce his holdings by up to 9,500 shares, accounting for 0.0088% of the total share capital [1] - Senior management Chen An plans to reduce his holdings by up to 11,200 shares, accounting for 0.0103% of the total share capital [2] Group 2 - As of the announcement, Baicheng Pharmaceutical's market capitalization is 6.8 billion yuan [3] - For the first half of 2025, the revenue composition of Baicheng Pharmaceutical is as follows: CRO business accounts for 86.22%, commercial production accounts for 10.28%, and CDMO business accounts for 3.5% [2]
百诚医药：董事兼高管贾飞拟减持不超过1.22万股